Exploring the Impact of a Usage Monitoring System Integrated into Home Oxigen Therapy on Pulmonary Hypertension Management in Patients with Interstitial Lung Disease

Exploring the Impact of a Usage Monitoring System Integrated into Home Oxigen Therapy on Pulmonary Hypertension Management in Patients with Interstitial Lung Disease - HOME-PH in ILD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061618

Enrollment

Registered

2026-05-18

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with interstitial lung disease who are receiving outpatient care at the Department of Respiratory Medicine, Institute of Science Tokyo (including the former Tokyo Medical and Dental University) Patients who have undergone or are scheduled to undergo echocardiographic examination Patients who will initiate use of a home oxygen monitoring tool during the study period, or patients already using a home oxygen monitoring tool but who have not previously received physician guidance based on monitoring data and will begin such guidance during the study period

Exclusion criteria

Exclusion criteria: Patients diagnosed with pulmonary hypertension other than Group 3 (Groups 1, 2, 4, or 5) Patients strongly suspected of having pulmonary hypertension other than Group 3 (Groups 1, 2, 4, or 5) Patients who do not provide informed consent for participation in the study Patients judged by the attending physician to have a prognosis unlikely to allow completion of the study period Patients unable to attend regular outpatient visits Patients considered inappropriate for participation by the principal investigator or co-investigators

Design outcomes

Primary

Measure	Time frame
Improvement in subjective symptoms Improvement in exercise capacity assessed using wearable devices Improvement in BNP levels Improvement in HOT usage status Comparison between usage duration during the initial assessment period and subsequent periods Comparison with activity duration measured by wearable devices Comparison with pre-study data collected retrospectively In patients using the DB-400 device, oxygen-related data will also be referenced Improvement in spirometric parameters Improvement in nocturnal SpO2 Improvement in inflammatory cytokine profiles Suppression of worsening TRPG assessed by echocardiography Improvement in the 6-minute walk test (6MWT)	—

Measure

Time frame

Improvement in subjective symptoms Improvement in exercise capacity assessed using wearable devices Improvement in BNP levels Improvement in HOT usage status Comparison between usage duration during the initial assessment period and subsequent periods Comparison with activity duration measured by wearable devices Comparison with pre-study data collected retrospectively In patients using the DB-400 device, oxygen-related data will also be referenced Improvement in spirometric parameters Improvement in nocturnal SpO2 Improvement in inflammatory cytokine profiles Suppression of worsening TRPG assessed by echocardiography Improvement in the 6-minute walk test (6MWT)

—

Countries

Japan

Contacts

Public ContactShiro Sonoda

Institute of Science Tokyo Hospital Department of Respiratory Medicine

sonoda.shiro@tmd.ac.jp0358035954

Outcome results